Neoadjuvant targeted therapy in patients with renal cell carcinoma

Cytoreductive nephrectomy as an independent option in patients with metastatic renal cell carcinoma (mRCC) cannot be considered as the only effective method, with rare exception, of a few patients with solitary metastases. Cytoreductive nephrectomy is now part of a multimodal approach encompassing surgical treatment and systemic drug therapy. Many retrospective and two prospective studies have demonstrated that it is expedient to perform cytoreductive nephrectomy. Immunotherapy should not be used as preoperatively in the era of cytokine therapy for mRCC due to that fact that it has no impact on primary tumor. In the current targeted therapy era, many investigators have concentrated attention
on the role of neoadjuvant targeted therapy for the treatment of patients with both localized and locally advanced mRCC. The potential benefits of neoadjuvant therapy for localized and locally advanced RCC include to make surgery easier and to increase the possibility of organsparing treatment, by decreasing the stage of primary tumor and the size of tumors. The possible potential advantages of neoadjuvant targeted therapy in patients with mRCC include prompt initiation of necessary systemic therapy; identification of patients with primary refractory tumors; and a preoperative reduction in the stage of primary tumor. Numerous retrospective and some prospective phase II studies have shown that neoadjuvant targeted therapy in patients with localized and locally advanced RCC is possible and tolerable and surgical treatment after neoadjuvant targeted therapy is safe and executable with a low incidence of complications. If neoadjuvant therapy is to be performed, it should be done within 2–4 months before surgery. Sorafenib and sunitinib are now most tested and suitable for neoadjuvant targeted therapy. Sorafenib is a more preferred drug due to its shorter half-life and accordingly to the possibility of discontinuing the drug immediately prior to surgery. Unquestionably, elaboration of precise recommendations for neoadjuvant therapy calls for further larger prospective studies estimating progression and survival rates in high-risk patients with localized and locally advanced RCC and in those with mRCC.

1. International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Доступно по адресу: http://globocan.iarc.fr/

2. Злокачественные новообразования в России в 2013 году: заболеваемость и смертность. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013: morbidity and mortality. Ed. A. D. Caprin, V. V. Starinskiy, G. V. Petrova. Moscow, 2015. (In Russ.)].

3. Flanigan R.C., Yonover P.M. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol

4. ;19(2):98–102.

5. Bex A., Powles T. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev. Anticancer Ther 2012; 12(6):787–97.

6. Flanigan R. C., Salmon S. E., Blumenstein B. A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001;345(23):1655–9.

7. Mickisch G. H., Garin A., Van Poppel H. et al. Radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–70.

8. Flanigan R. C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.

9. Motzer R. J., Bukowski R. M., Figlin R. A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113(7): 1552–8.

10. Wood C. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2001; 13(2 Pt 2):697–702.

11. Zini L., Capitanio U., Perrotte P. et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009;73(2): 342–6.

12. Choueiri T. K., Xie W., Kollmannsberger C. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185(1):60–6.

13. Warren M., Venner P. M., North S. et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2001;3(4):281–9.

14. Aben K. K., Heskamp S., Janssen-Heijnen M. L. et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011;47(13):2023–32.

15. Kutikov A., Uzzo R. G., Caraway A. et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 2010;106(2):218–23.

16. Abdollah F., Sun M., Thuret R. et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol 2011;18(10):2988–96.

17. Mizutani Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int J Urol 2009;16:444–8.

18. Sonpavde G., Sternberg C. N. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010;106:6–22.

19. Shuch B., Riggs S. B., LaRochelle J.C. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008;102:692–6.

20. Schrader A. J., Steffens S., Schnoeller T. J. et al. Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy? Int J Urol 2012;19:903–7.

21. Silberstein J. L., Millard F., Mehrazin R. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 2010;106:1270–6.

22. Hellenthal N. J., Underwood W., Penetrante R. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184:859–64.

23. Bex A., van der Veldt A. A., Blank C. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009;27:533–9.

24. Powles T., Kayani I., Blank C. et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011;22: 1041–7.

25. Margulis V., Matin S. F., Tannir N. et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008;180:94–8.

26. Chapin B. F., Delacroix S. E.Jr, Culp S. H. et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011;60:964–71.

27. Wood C. G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009;115:2355–60.

28. Abel E. J., Culp S. H., Tannir N. M. et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10–5.

29. Harshman L. C., Yu R. J., Allen G. I. et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol 2011.

30. Karakiewicz P. I., Suardi N., Jeldres C. et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845–8.

31. Di Silverio F., Sciarra A., Parente U. et al. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol. Int. 2008;80: 451–3.

32. Kondo T., Hashimoto Y., Kobayashi H. et al. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn J Clin Oncol 2010;40:1173–9.

33. Harshman L. C., Srinivas S., Kamaya A., Chung B. I. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009;6:338–43.

34. Robert G., Gabbay G., Bram R. et al. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009;55:1477–80.

35. Bex A., van der Veldt A. A., Blank C. et al. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma ыon pretreatment with sunitinib. Acta Oncol 2010;49:520–3.

36. Cost N. G., Delacroix S. E.Jr, Sleeper J. P. et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 2011;59:912–8.

37. Cowey C. L., Amin C., Pruthi R. S. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28:1502–7.

38. Thomas A. A., Rini B. I., Stephenson A. J. et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182(3):881–6.

39. Amin C., Wallen E., Pruthi R. S. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008;72(4):864–8.

40. Jonasch E., Wood C. G., Matin S. F. et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076–81.

41. Powles T., Sarwar N., Stockdale A. et al. Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study. J Clin Oncol 2013;31 (suppl; abstr 4508).

42. Rini B. I., Plimack E. R., Takagi T. et al. A phase ii study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015 Mar 23. pii: S0022–5347(15) 03398–4.

43. Alvarez A. L., Plimack E. R., Dreicer R. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to enable partial nephrectomy. J Clin Oncol 2014;32:5 (suppl; abstr 4522).

44. Karam J. A., Devine C. E., Urbauer D. L. et al. Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2014;32:441.

45. Lane B. R., Derweesh I. H., Kim H. L. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol 2015;33(3):112. e15–21.